Results 221 to 230 of about 14,538,270 (379)

Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021

Arthritis Care &Research, EarlyView.
Objective Systemic sclerosis (SSc) is a rare autoimmune disease characterized by tissue fibrosis, vasculopathy, and immune dysregulation. Our objectives were to quantify the overall and site‐specific cancer risks in patients with SSc compared to the general population, examine temporal trends in cancer incidence following SSc diagnosis, and explore ...
Jihyun Na, Su Jin Choi, Sojeong Park, Minae Park, Doo‐Ho Lim   +4 more
wiley   +1 more source

Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties. [PDF]

Nat Commun
Aaen KH, Testa MF, Nilsen J, Tarantino R, Canepari C, Benedusi M, Benjakul S, Nyquist-Andersen M, Herigstad ML, Cantore A, Valacchi G, Sandlie I, Bernardi F, Pinotti M, Branchini A, Andersen JT.   +15 more
europepmc   +1 more source

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. [PDF]

Blood Adv, 2023
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key NS, Lattimore SU, Leebeek FWG, Miesbach WA, Recht M, Gut R, Dolmetsch R, Monahan PE, Le Quellec S, Pipe SW.   +13 more
europepmc   +1 more source

The effect of platelets in the activation of human blood coagulation factor IX by factor XIa [PDF]

, 1986
Hans Soons, T Janssen-Claessen, H.C. Hemker, Guido Tans   +3 more
openalex   +1 more source

Serum uric acid levels in older adults: Associations with clinical outcomes and implications for reference intervals in those aged 70 years and over

Arthritis Care &Research, Accepted Article.
Objectives Reports have linked both high and low serum uric acid (SUA) levels to adverse health outcomes. This study aimed to establish a reference interval for SUA in older adults and assessed its association with clinically relevant outcomes in relatively healthy, community‐dwelling individuals aged 70 and older.
Amanda J Rickard, Cammie Tran, Hans G Schneider, Flavia M Cicuttini, Anita E Wluka, Ego Seeman, Johannes T Neumann, Md Nazmul Karim, Zhen Zhou, Sultana Monira Hussain, David P Q Clark, Daniel Clayton‐Chubb, Andrew M Tonkin, Lawrence J Beilin, Robyn L Woods, John J McNeil   +15 more
wiley   +1 more source

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B. [PDF]

Clin Pharmacokinet
Wojciechowski J, Gaitonde P, Hughes JH, Ravva P.   +3 more
europepmc   +1 more source

Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies. [PDF]

Blood Adv, 2023
Foley JH, Shehu E, Riddell A, Gray E, Goodale A, Yu IM, Verhoef D, Little J, Shattock D, Kitchen S, Chowdary P, Corbau R, Nathwani AC.   +12 more
europepmc   +1 more source

Hemophilia B with inhibitor: molecular analysis of the subtotal deletion of the factor IX gene [PDF]

, 1985
H. J. Hassan, A Leonardi, R Guerriero, C Chelucci, L Cianetti, N Ciavarella, P Ranieri, D Pilolli, C Peschle   +8 more
openalex   +1 more source

The Economic Burden of Rheumatoid Arthritis in Low‐ and Middle‐Income Countries: Systematic Review and Meta‐Analysis

Arthritis Care &Research, Accepted Article.
Objective The aim of this systematic review was to synthesise the economic impact of rheumatoid arthritis (RA) on households, health systems, and society in low‐ and middle‐income countries (LMICs). Methods Electronic databases such as PubMed, Web of Science, and CINAHL were searched using keywords related to RA and cost of illness.
Tadesse Gebrye, Chidozie E.Mbada, Clara T.Fatoye, Faatihah Niyi‐Odumosu, Ushotanefe Useh, Zalmai Hakimi, Francis Fatoye   +6 more
wiley   +1 more source

Extravascular factor IX after gene therapy in hemophilia B, does it matter? [PDF]

Res Pract Thromb Haemost
Van Thillo Q, Hermans C.
europepmc   +1 more source